GlassScriptPhysician profile
Barbara I Rappaport
NPI 1578585147
$1,728.37
in general payments reported to CMS, 2019-2025
20 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $279 · 2021: $229 · 2022: $122 · 2023: $268 · 2024: $285 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $312.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Edwards Lifesciences Corporation | $287.60 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $266.78 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.71 | 2021-2024 | Jardiance, Synjardy |
| Endo Pharmaceuticals INC. | $120.01 | 2020-2022 | |
| Pfizer INC. | $98.62 | 2024-2025 | |
| Novo Nordisk INC | $73.29 | 2020-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $62.81 | 2022-2023 | Korlym |
| Exact Sciences Corporation | $50.51 | 2023-2025 | Cologuard Collection Kit |
| Apellis Pharmaceuticals, INC. | $48.06 | 2023-2024 | Syfovre |
| Abbvie INC. | $46.56 | 2022 | |
| Gilead Sciences, INC. | $31.46 | 2020-2021 | |
| Ibsa Pharma INC. | $31.09 | 2023 | Tirosint, Licart |
| Allergan, INC. | $28.15 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.36 | 2025 | Izervay |
| Abbott Laboratories | $24.83 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $18.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.02 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Rappaport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.